E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Gastrointestinal Anastomosis Leak |
|
E.1.1.1 | Medical condition in easily understood language |
Sealing of joined ends of the colon |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and effectiveness of EVICEL® Fibrin Sealant (Human) for use as an adjunct to stapled anastomosis after lower anterior resection (LAR).
This will be done by assessing the absence of clinical anastomotic leak (success) within 40 days post operatively.
Clinical anastomotic leak is defined as signs and symptoms that are confirmed by one or more of the following methods:
• Confirmation on imaging;
• Visual confirmation (eg., reoperation/drain output). |
|
E.2.2 | Secondary objectives of the trial |
- Incidence of adverse events up to post operative Day 90;
- Incidence of clinical anastomotic leak within 90 days post operatively;
- Incidence of stricture (up to post operative Day 90);
- Incidence of post operative intervention related to clinical anastomotic leak or stricture (percutanous drainage, intraluminal stenting or reoperation), up to post operative Day 90. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Preoperative:
1) Subjects undergoing primary elective lower anterior resection with a stapled end-to-end or end-to-side anastomosis;
2) Subjects ≥ 18 years of age who are willing to participate in the study and provide written informed consent prior to any study-related procedures;
Intraoperative:
3) Confirmed distance of anastomosis is ≤12cm from the anal verge, as measured using a rigid scope or non-flexible scope alternative.
4) Anastomosis with a successful leak test. |
|
E.4 | Principal exclusion criteria |
Pre-operative:
1) Avastin use within 30 days prior to surgery;
2) Known hypersensitivity to the human blood products or the components of the investigational product;
3) Female subjects who are pregnant or nursing;
4) Exposure to another investigational drug or device in a clinical trial within 30 days prior to surgery or planned/intended for the 90 day follow up period after surgery.
Intra-operative:
5) Subject requiring protective ostomy;
6) Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedures.
7) Use of any fibrin sealant for haemostasis during the surgical procedure. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of subjects with absence of clinical anastomotic leak within 40 days post-operatively. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Within 40 days post-operatively. |
|
E.5.2 | Secondary end point(s) |
- Incidence of adverse events up to post operative Day 90;
- Incidence of clinical anastomotic leak within 90 days post operatively;
- Incidence of stricture (up to post operative Day 90);
- Incidence of post operative intervention related to clinical anastomotic leak or stricture (percutanous drainage, intraluminal stenting or reoperation), up to post operative Day 90. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
76 -104 days post-operatively. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 7 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Korea, Republic of |
New Zealand |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Day 90 visit. Althought the study is concluded after 90 days post-operatively, all subjects will be followed specifically and only to ascertain stricture information at 180 and 360 days. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 4 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 4 |